COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 1 of 2 for:    PRN1008 pemphigus
Previous Study | Return to List | Next Study

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02704429
Recruitment Status : Completed
First Posted : March 10, 2016
Last Update Posted : December 8, 2020
Principia Biopharma Australia Pty Ltd.
Information provided by (Responsible Party):
Principia Biopharma Inc.

Brief Summary:
Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue treatment", if indicated. The duration of therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase, Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.

Condition or disease Intervention/treatment Phase
Pemphigus Vulgaris Drug: PRN1008 Phase 2

Detailed Description:

Primary Objectives:

To evaluate the safety of PRN1008 in patients with pemphigus vulgaris (PV) To evaluate the clinical activity of PRN1008 in patients with PV, per criteria in the European Academy of Dermatology and Venereology (EADV) 2014 Pemphigus S2 Guideline (Hertl et al. 2015)

Secondary Objectives To evaluate the pharmacokinetics (PK) and the pharmacodynamics (PD) of multiple doses of PRN1008 in patients with PV To evaluate the relationship of PK and PD to each other and to efficacy and safety in this patient population

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Part A with 12 weeks treatment and 12 weeks follow-up. Part B with 24 weeks treatment and 4 weeks follow-up.
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris
Actual Study Start Date : January 22, 2016
Actual Primary Completion Date : December 2019
Actual Study Completion Date : January 10, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pemphigus

Arm Intervention/treatment
Experimental: PRN1008
Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
Drug: PRN1008
Part A: PRN1008, oral dose, 12 weeks; Part B: PRN1008, oral dose 24 weeks
Other Name: BTK inhibitor

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events [ Time Frame: Part A: 24 week treatment ]
    The incidence of treatment-emergent adverse events (TEAEs), including clinically significant changes in physical examination, laboratory tests, and vital signs.

  2. Control of disease activity at 4 weeks [ Time Frame: 4 weeks treatment ]
    The proportion of subjects who are able to achieve control of disease activity (CDA) within 4 weeks of starting PRN1008 treatment without the need for doses of prednisone or prednisolone >0.5 mg/kg.

Secondary Outcome Measures :
  1. Time to control of disease activity (CDA) [ Time Frame: Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up ]
    Time to control of disease activity (CDA) defined in EADV 2015 Pemphigus S2 Guideline

  2. Time to end of consolidation phase [ Time Frame: Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up ]
    Time to end of consolidation phase as defined in EADV 2015 Pemphigus S2 Guideline

  3. Time to complete response [ Time Frame: Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up ]
    Time to complete response as defined in EADV 2015 Pemphigus S2 Guideline

  4. Time to relapse after PRN1008 treatment discontinuation [ Time Frame: Part A: 12 week follow up and Part B: 4 week follow-up ]
    Time to relapse after PRN1008 treatment discontinuation

  5. Cumulative corticosteroid usage [ Time Frame: Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up ]
    Cumulative corticosteroid usage

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:

    • newly diagnosed patients (i.e. naïve to an effective induction treatment regimen) for whom an initial period of PRN1008 monotherapy is judged clinically acceptable, or
    • relapsing patients, for whom an initial period of PRN1008 monotherapy, or combination therapy with any of low dose corticosteroid (≤ 10 mg/day),

Exclusion Criteria:

  • Pregnant or lactating women
  • A history of malignancy of any type, other than surgically excised non-melanoma skin cancers or in situ cervical cancer within 5 years before the day of dosing
  • Use of immunologic response modifiers with the following periods prior to Day 1: 1 week: cyclophosphamide; 4 weeks: intravenous immunoglobulin, Kinaret (anakinra) and Enbrel (etanercept); 12 weeks: Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept), Actemra (tocilizumab), Cimzia (certolizumab), Cosentyx (secukinumab), plasmapheresis; 6 months: Rituxan/MabThera (rituximab), ofatumumab, any other anti-CD20 antibody, other long acting biologics
  • Use of >10 mg per day of oral prednisolone per day within 2 weeks prior to Day 1 (inhaled and mucosal [for symptomatic treatment of oral lesions] corticosteroids are allowed)
  • Use of proton pump inhibitor drugs such as omeprazole and esomeprazole
  • Has received any investigational drug (or is currently using an investigational device) within the 30 days before receiving the first dose of study medication, or at least 5 times the respective elimination half-life time (whichever is longer)
  • History of drug abuse within the precious 12 months
  • Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day
  • Refractory nausea and vomiting, malabsorption, external biliary shunt, significant bowel resection that would preclude adequate study drug absorption
  • History of anorexia nervosa or periods of there months or more of low body weight (BMI<17.5)
  • Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1
  • History of solid organ transplant
  • History of epilepsy or other forms of seizures in the last 5 years
  • Positive for screening for human immunodeficiency virus, hepatitis B (surface and core antibodies unrelated to vaccination), or hepatitis C (anti-HCV antibody confirmed with Hep C RNA)
  • History of active or latent tuberculosis (TB) infection (must test negative using the QuantiFERON test to be eligible)
  • History of serious infections requiring intravenous (by catheter that delivers antibiotics into your blood) treatment
  • Live vaccine within 28 days prior to baseline or plan to receive one during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02704429

Layout table for location information
Australia, New South Wales
Premier Specialists
Kogarah, New South Wales, Australia, 2217
Australia, Victoria
Sinclair Dermatology
East Melbourne, Victoria, Australia, 3002
Royal Melbourne, Dermatology Office
Melbourne, Victoria, Australia, 3050
Clinical Hospital Osijek
Osijek, Croatia, 31000
Klinichki Bolnicki Centar Zagreb
Zagreb, Croatia, 10 000
Hôpital Avicenne
Bobigny, Siene-Saint Denis, France, 93009
Rouen University Hospital
Rouen, France, 76038
University General Hospital of Ioannina
Ioánnina, Ioannina, Greece, 45500
University Hospital of Larissa
Larissa, Thessaly, Greece, 41110
Hospital of Venereal and Skin Diseases A.Syggros
Athens, Greece, 16121
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, Greece, 56429
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Principia Biopharma Inc.
Principia Biopharma Australia Pty Ltd.
Layout table for investigator information
Study Director: Dolca Thomas, MD Principia Biopharma
Layout table for additonal information
Responsible Party: Principia Biopharma Inc. Identifier: NCT02704429    
Other Study ID Numbers: PRN1008-005
First Posted: March 10, 2016    Key Record Dates
Last Update Posted: December 8, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Vesiculobullous
Skin Diseases
Autoimmune Diseases
Immune System Diseases